By the Mindtek Research team · Scientifically reviewed · ~4 min read
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a sequence identified in human gastric juice. It is one of the most extensively studied “cytoprotective” peptides in the preclinical literature. This note summarises the mechanistic evidence from animal and in-vitro studies. It describes research findings only and makes no therapeutic or clinical claims.
Angiogenesis via the VEGFR2 axis
Across rodent models of muscle, tendon and vascular injury, BPC-157 has been reported to promote new blood-vessel formation. In-vitro work indicates this is mediated, at least in part, through vascular endothelial growth factor receptor-2 (VEGFR2) signalling and downstream nitric-oxide pathways (Huang et al., 2015). Inference: enhanced angiogenesis plausibly contributes to the accelerated tissue repair seen in these models, though human relevance remains unestablished.
Tendon fibroblast survival and migration
In cultured Achilles-tendon fibroblasts, BPC-157 increased cell survival, spreading and migration, with upregulation of the FAK–paxillin pathway and growth-factor receptor expression (Chang et al., 2011). These are cell-culture and rodent observations — a mechanistic signal, not a demonstration of human efficacy.
The consistent thread across models is a pro-angiogenic, pro-migratory phenotype — the cellular groundwork of repair.
A gut-derived peptide with unusual stability
BPC-157 was first characterised for gastrointestinal cytoprotection (Sikiric and colleagues). Its reported stability in gastric juice is atypical for a peptide and is part of why it has been explored across so many tissue-injury paradigms.
What the evidence does — and does not — show
Data: reproducible effects in rodent and in-vitro injury models. Gap: human clinical-trial data are limited, and no regulatory body has evaluated BPC-157 for any therapeutic use. Any extrapolation of dose or effect to humans is speculative and outside the scope of research supply.
References. Chang C-H, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing. J Appl Physiol, 2011. · Huang T, et al. Body protective compound-157 enhances angiogenesis (VEGFR2/Akt/eNOS). Drug Des Devel Ther, 2015. · Sikiric P, et al. Stable gastric pentadecapeptide BPC 157. Curr Pharm Des, 2011.
For research and educational use only. Not for human consumption. Not evaluated by any regulatory body. No therapeutic claims are made. Batch-specific GC-MS and HPLC (≥98%) certificates of analysis are available on request.